A serine palmitoyltransferase inhibitor blocks hepatitis C virus replication in human hepatocytes

Gastroenterology

Volumn 145, Issue 4, 2013, Pages 865-873

  Katsume, Asao ^a,b   Tokunaga, Yuko ^a   Hirata, Yuichi ^a   Munakata, Tsubasa ^a   Saito, Makoto ^a   Hayashi, Hitohisa ^a   Okamoto, Koichi ^b   Ohmori, Yusuke ^b   Kusanagi, Isamu ^c   Fujiwara, Shinya ^b   Tsukuda, Takuo ^b   Aoki, Yuko ^b   Klumpp, Klaus ^d   Tsukiyama Kohara, Kyoko ^e   El Gohary, Ahmed ^f   Sudoh, Masayuki ^b   Kohara, Michinori ^a  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^b CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^c Chugai Research Institute for Medical Science Inc   (Japan)

^d HOFFMANN LA ROCHE INC   (United States)

^e KAGOSHIMA UNIVERSITY   (Japan)

^f Suez Canal University Faculty of Medicine   (Egypt)

Author keywords

Direct Acting Antiviral Agents DAAs HCV Lifecycle Drug

Indexed keywords

ANTIVIRUS AGENT; NA 808; NESBUVIR; PEGINTERFERON ALPHA2A; SERINE PALMITOYLTRANSFERASE; SPHINGOLIPID; TELAPREVIR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG INHIBITION; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IC 50; LIVER CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REPLICON; VIRUS LOAD; VIRUS REPLICATION;

EID: 84884416526     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2013.06.012     Document Type: Article

References (28)

1. A. Wasley, and M.J. Alter Epidemiology of hepatitis C: geographic differences and temporal trends Semin Liver Dis 20 2000 1 16
2. M.J. Alter, D. Kruszon-Moran, and O.V. Nainan The prevalence of hepatitis C virus infection in the United States, 1988 through 1994 N Engl J Med 341 1999 556 562
3. M.W. Fried, M.L. Shiffman, and K.R. Reddy Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
4. M.P. Manns, J.G. McHutchison, and S.C. Gordon Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965
5. C. Hezode, N. Forestier, and G. Dusheiko Telaprevir and peginterferon with or without ribavirin for chronic HCV infection N Engl J Med 360 2009 1839 1850
6. Kwo P, Lawitz J, McCone J, et al. 44th Annual Meeting of the European Association for the Study of the Liver, Copenhagen, Denmark, 22 to 26 April 2009, abstract 4.
7. C. Sarrazin, and S. Zeuzem Resistance to direct antiviral agents in patients with hepatitis C virus infection Gastroenterology 138 2010 447 462
8. J.M. Pawlotsky Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus Hepatology 53 2011 1742 1751
9. S. Zeuzem, P. Buggisch, and K. Agarwal The protease inhibitor GS-9256 and non-nucleoside polymerase inhibitor tegobuvir alone, with RBV or peginterferon plus RBV in hepatitis C Hepatology 55 2012 749 758
10. E.J. Gane, S.K. Roberts, and C.A. Stedman Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial Lancet 376 2010 1467 1475
11. J.M. Gottwein, T.K. Scheel, and T.J. Jensen Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses Gastroenterology 141 2011 1067 1079
12. H. Sakamoto, K. Okamoto, and M. Aoki Host sphingolipid biosynthesis as a target for hepatitis C virus therapy Nat Chem Biol 1 2005 333 337
13. K. Klumpp, G. Kalayanov, and H. Ma 2'-deoxy-4'-azido nucleoside analogs are highly potent inhibitors of hepatitis C virus replication despite the lack of 2'-alpha-hydroxyl groups J Biol Chem 283 2008 2167 2175
14. T. Watanabe, M. Sudoh, and M. Miyagishi Intracellular-diced dsRNA has enhanced efficacy for silencing HCV RNA and overcomes variation in the viral genotype Gene Ther 13 2006 883 892
15. T. Takeuchi, A. Katsume, and T. Tanaka Real-time detection system for quantification of hepatitis C virus genome Gastroenterology 116 1999 636 642
16. P. Halfon, and S. Lacarnini Hepatitis C virus resistance to protease inhibitors J Hepatol 55 2011 192 206
17. K. Inoue, T. Umehara, and U.T. Ruegg Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo Hepatology 45 2007 921 928
18. Y. Hirata, K. Ikeda, and M. Sudoh Self-enhancement of hepatitis C virus replication by promotion of specific sphingolipid biosynthesis PLoS Pathog 8 2012 e100286
19. H. Aizaki, K. Morikawa, and M. Fukasawa Critical role of virion-associated cholesterol and sphingomyelin in hepatitis C virus infection J Virol 82 2008 5715 5724
20. F.G. Tafesse, S. Sanyal, and J. Ashour Intact sphingomyelin biosynthetic pathway is essential for intracellular transport of influenza virus glycoproteins Proc Natl Acad Sci U S A 110 2013 6406 6411
21. M.E. Miller, S. Adhikary, and A.A. Kolokoltsov Ebolavirus requires acid sphingomyelinase activity and plasma membrane sphingomyelin for infection J Virol 86 2012 7473 7483
22. S.A. Villano, D. Raible, and D. Harper Antiviral activity of the non-nucleoside polymerase inhibitor, HCV-796, in combination with pegylated interferon alfa-2b in treatment-naive patients with chronic HCV J Hepatol 46 2007 S24
23. S.T. Shi, K.J. Herlihy, and J.P. Graham Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase Antimicrob Agents Chemother 53 2009 2544 2552
24. S. Le Pogam, A. Seshaadri, and A. Ewing RG7128 alone or in combination with pegylated interferon-alpha 2a and ribavirin prevents hepatitis C virus (HCV) replication and selection of resistant variants in HCV-infected patients J Infect Dis 202 2010 1510 1519
25. A.M. Lam, E. Murakami, and C. Espiritu PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro- 2'-C-methyluridine monophosphate: a potent and pan-genotype inhibitor of hepatitis C virus replication Antimicrob Agents Chemother 54 2010 3187 3196
26. M.R. Hojjati, Z. Li, and X.C. Jiang Serine palmitoyl-CoA transferase (SPT) deficiency and sphingolipid levels in mice Biochim Biophys Acta 1737 2005 44 51
27. E. Ohta, T. Ohira, and K. Matsue Analysis of development of lesions in mice with serine palmitoyltransferase (SPT) deficiency -Sptlc2 conditional knockout mice- Exp Anim 58 2009 515 524
28. K. Ozeki, K. Okano, and N. Ohminato The mechanism of the liver specific distribution of NA808, a first-in-class serine palmitoyltransferase inhibitor, mediated by organic anion transporter 1B1-multidrug resistance associated protein 2 Hepatology 54 2011 550A Technology